MAOI treatment response

multiaxial assessment

Earl Giller, Donald Bialos, Mark A Riddle, Merilyne C. Waldo

Research output: Contribution to journalArticle

Abstract

While studying the effectiveness of the MAOI isocarboxazid for the treatment of depression, we noted that many patients experienced a reduction of symptoms without equivalent improvement in other areas of their lives. We evaluated four outcome areas: symptoms, work, family functioning and social functioning. After 6 weeks on medication, symptoms improved the most, significantly more so than the other three areas. For the group of patients who completed 24 weeks on medication, all four outcome areas were further improved compared to the 6-week levels, with the improvement in work functioning reaching statistical significance. We conclude that the assessment of treatment outcome is more complex than the simple measurement of symptom reduction, and that different outcome areas are likely to improve at different rates and to different extents.

Original languageEnglish (US)
Pages (from-to)171-175
Number of pages5
JournalJournal of Affective Disorders
Volume14
Issue number2
DOIs
StatePublished - 1988
Externally publishedYes

Fingerprint

Isocarboxazid
Depression
Therapeutics

Keywords

  • Monoamine oxidase inhibitor treatment
  • Multiaxial assessment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

MAOI treatment response : multiaxial assessment. / Giller, Earl; Bialos, Donald; Riddle, Mark A; Waldo, Merilyne C.

In: Journal of Affective Disorders, Vol. 14, No. 2, 1988, p. 171-175.

Research output: Contribution to journalArticle

Giller, Earl ; Bialos, Donald ; Riddle, Mark A ; Waldo, Merilyne C. / MAOI treatment response : multiaxial assessment. In: Journal of Affective Disorders. 1988 ; Vol. 14, No. 2. pp. 171-175.
@article{86bd4f7104b54d6aa2d70515bfaad23d,
title = "MAOI treatment response: multiaxial assessment",
abstract = "While studying the effectiveness of the MAOI isocarboxazid for the treatment of depression, we noted that many patients experienced a reduction of symptoms without equivalent improvement in other areas of their lives. We evaluated four outcome areas: symptoms, work, family functioning and social functioning. After 6 weeks on medication, symptoms improved the most, significantly more so than the other three areas. For the group of patients who completed 24 weeks on medication, all four outcome areas were further improved compared to the 6-week levels, with the improvement in work functioning reaching statistical significance. We conclude that the assessment of treatment outcome is more complex than the simple measurement of symptom reduction, and that different outcome areas are likely to improve at different rates and to different extents.",
keywords = "Monoamine oxidase inhibitor treatment, Multiaxial assessment",
author = "Earl Giller and Donald Bialos and Riddle, {Mark A} and Waldo, {Merilyne C.}",
year = "1988",
doi = "10.1016/0165-0327(88)90060-2",
language = "English (US)",
volume = "14",
pages = "171--175",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - MAOI treatment response

T2 - multiaxial assessment

AU - Giller, Earl

AU - Bialos, Donald

AU - Riddle, Mark A

AU - Waldo, Merilyne C.

PY - 1988

Y1 - 1988

N2 - While studying the effectiveness of the MAOI isocarboxazid for the treatment of depression, we noted that many patients experienced a reduction of symptoms without equivalent improvement in other areas of their lives. We evaluated four outcome areas: symptoms, work, family functioning and social functioning. After 6 weeks on medication, symptoms improved the most, significantly more so than the other three areas. For the group of patients who completed 24 weeks on medication, all four outcome areas were further improved compared to the 6-week levels, with the improvement in work functioning reaching statistical significance. We conclude that the assessment of treatment outcome is more complex than the simple measurement of symptom reduction, and that different outcome areas are likely to improve at different rates and to different extents.

AB - While studying the effectiveness of the MAOI isocarboxazid for the treatment of depression, we noted that many patients experienced a reduction of symptoms without equivalent improvement in other areas of their lives. We evaluated four outcome areas: symptoms, work, family functioning and social functioning. After 6 weeks on medication, symptoms improved the most, significantly more so than the other three areas. For the group of patients who completed 24 weeks on medication, all four outcome areas were further improved compared to the 6-week levels, with the improvement in work functioning reaching statistical significance. We conclude that the assessment of treatment outcome is more complex than the simple measurement of symptom reduction, and that different outcome areas are likely to improve at different rates and to different extents.

KW - Monoamine oxidase inhibitor treatment

KW - Multiaxial assessment

UR - http://www.scopus.com/inward/record.url?scp=0023861065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023861065&partnerID=8YFLogxK

U2 - 10.1016/0165-0327(88)90060-2

DO - 10.1016/0165-0327(88)90060-2

M3 - Article

VL - 14

SP - 171

EP - 175

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 2

ER -